Acucela founder fights to regain control; Biotech insiders fret over signs of a "bubble";

@FierceBiotech: Baxter and its controversial partner CTI claim a win in PhIII blood cancer study. Report | Follow @FierceBiotech

@JohnCFierce: From the weekend file: UPDATED: Merck to shutter Cubist unit in May, axing most of the 128 R&D staffers. Report | Follow @JohnCFierce

@DamianFierce: Hey @FierceBiotech's podcast is now available on Stitcher. If you know what that means, here you go. | Follow @DamianFierce

> The Seattle Times reports on the legal struggle going on for control of Acucela, pitting founder Ryo Kubota against some big investors. Kubota was ousted from his job as CEO in December after the company went public in Japan. Story

> Biotech's overnight wonders in the IPO world are beginning to make some insiders think we're in a bubble, reports Bloomberg. Report

Medical Device News

@FierceMedDev: ICYMI Friday: J&J ordered to hand over $5.6M in vaginal mesh trial. Report | Follow @FierceMedDev

@VarunSaxena2: Four clinical trial patients die in test of Sunshine Heart ventricle assist device. Story | Follow @VarunSaxena2

@EmilyWFierce: Get this week's edition of FierceLifeSci here! | Follow @EmilyWFierce

> Patient advocates call for increased transparency as superbug tied to endoscopes continues. News

> FDA approves novel blood purifier that treats rare condition in hemodialysis patients. Story

> Icon launches new medical device research division. Article

Pharma News

@FiercePharma: Roche neighbors sue, claiming contamination lowered home prices. More | Follow @FiercePharma

@EricPFierce: ICYMI: MS Pharma in Jordan gets $30M development loan to expand its drug manufacturing. Story | Follow @EricPFierce

@CarlyHFierce: German court deals another EU patent blow to Lilly's blockbuster Alimta. Article | Follow @CarlyHFierce

> GSK sacks 100-plus China workers for misconduct in wake of bribery scandal. News

> Novartis CEO eyes more cost cuts to satisfy margin demands. Story

> Opdivo's survival benefit inspired FDA to act fast on NSCLC approval: Pazdur. More

Biotech IT News

> NIH puts data stitching at top of precision medicine to-do list. More

> Broadly positive reactions roll in for FDA's drug shortages app. Report

> Ubisoft creates therapeutic video game to treat lazy eye. Item

> Intel-GE joint venture teams with Xavier U. to test health tech. Story

> AstraZeneca's rapid-fire IT dealmaking continues with Elixir hookup. Article

CRO News

> Altasciences partners up for early-stage R&D. Article

> Contractor Almac gets into the clinic with a candidate of its own. More

> Icon doubles down on med tech with latest offering. Story

> Patheon snags another CMO amid its global expansion. News

> WuXi eyes major growth in 2015 with plans to spend big. Article

Animal Health News

> Heska scores record 2014 sales on 'more focused' strategy. More

> EMA seeks input on new guidelines to combat antibiotics resistance. Item

> Researchers tap dogs for insights into stopping cancer metastasis. Article

> Future veterinarians go to Congress to discuss student loan debt. Story

> McDonald's ditches antibiotics-raised chicken as legislators launch bill to curb use. Report

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.